| Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRK | Common Stock | Options Exercise | $0 | +235K | +33.54% | $0.00 | 936K | Nov 3, 2022 | Direct | |
| transaction | MRK | Common Stock | Sale | -$21.2M | -215K | -22.94% | $98.68 | 721K | Nov 3, 2022 | Direct | F1 |
| transaction | MRK | Common Stock | Sale | -$2.02M | -20.4K | -2.83% | $99.09 | 701K | Nov 3, 2022 | Direct | F2 |
| transaction | MRK | Common Stock | Options Exercise | $0 | +235K | +33.54% | $0.00 | 936K | Nov 4, 2022 | Direct | |
| transaction | MRK | Common Stock | Sale | -$19.7M | -200K | -21.4% | $98.53 | 735K | Nov 4, 2022 | Direct | F3 |
| transaction | MRK | Common Stock | Sale | -$3.45M | -34.8K | -4.73% | $99.08 | 701K | Nov 4, 2022 | Direct | F4, F5 |
| holding | MRK | Common Stock - 401(k) Plan | 4.48K | Nov 3, 2022 | By 401(k) | F6 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRK | Stock Option (Right to Buy) | Options Exercise | $0 | -235K | -33.3% | $0.00 | 471K | Nov 3, 2022 | Common Stock | 235K | $53.06 | Direct | F7 |
| transaction | MRK | Stock Option (Right to Buy) | Options Exercise | $0 | -235K | -49.92% | $0.00 | 236K | Nov 4, 2022 | Common Stock | 235K | $53.06 | Direct | F7 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.0500 to $99.0500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.0600 to $99.2000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.9700 to $98.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.9800 to $99.2800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| F5 | Holdings include shares acquired in dividend reinvestment transactions. |
| F6 | Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan. |
| F7 | The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. |